Company Overview

KP Tissue Inc. is a Canadian holding company that owns an equity interest in Kruger Products L.P., one of Canada’s largest manufacturers and distributors of tissue products for household, industrial, and commercial use. The company operates within the consumer staples and paper products industries, with revenue exposure tied primarily to bathroom tissue, facial tissue, paper towels, and napkins sold under well-known brands such as Cashmere, Purex, Scotties, SpongeTowels, and White Swan. KP Tissue itself does not directly manufacture products; instead, its financial performance is substantially derived from its ownership stake in Kruger Products L.P., which conducts the underlying operating business.

The company primarily serves retail consumers, commercial institutions, and away-from-home customers across Canada and selected international markets. Its strategic positioning is supported by strong brand recognition in the Canadian tissue market, vertically integrated manufacturing capabilities through its operating partnership, and longstanding relationships with major retailers. KP Tissue was established in 2012 as part of a corporate restructuring involving Kruger Products L.P. and became publicly traded on the Toronto Stock Exchange under the symbol KPT. Public filings and investor materials consistently identify the company’s role as an investment vehicle providing exposure to the Canadian tissue products market.

Business Operations

KP Tissue generates substantially all of its earnings through its ownership interest in Kruger Products L.P., which operates through consumer and away-from-home tissue product businesses. The operating partnership manufactures and distributes branded and private-label tissue products across multiple categories, including bathroom tissue, paper towels, facial tissue, and napkins. Revenue is driven primarily by consumer retail sales in Canada, supplemented by commercial and institutional sales to offices, healthcare facilities, hospitality providers, and industrial customers. The company’s operational footprint includes tissue converting facilities, paper mills, and distribution infrastructure located primarily in Canada and the United States.

The business maintains domestic operations throughout Canada while also supporting U.S. manufacturing and distribution activities through subsidiaries and production facilities. Kruger Products L.P. controls key manufacturing assets and production technologies related to tissue conversion and paper processing. The company has historically maintained strategic commercial relationships with large Canadian retailers and wholesalers, while also participating in private-label supply arrangements. Public disclosures identify operational investments focused on production efficiency, automation, and expansion of premium tissue capacity.

Strategic Position & Investments

KP Tissue’s strategic direction is closely aligned with the growth initiatives of Kruger Products L.P., particularly investments intended to expand manufacturing scale, strengthen premium product offerings, and improve operational efficiency. A major strategic initiative in recent years has been the expansion of tissue manufacturing capacity in Canada, including investments associated with the Sherbrooke expansion project in Québec. This project included the deployment of advanced tissue manufacturing technology and additional converting capacity intended to support long-term demand growth and improve production economics.

The company’s investment exposure is concentrated in the tissue products sector rather than a diversified portfolio structure. Through Kruger Products L.P., the business continues to focus on innovation in sustainable tissue products, operational modernization, and premium consumer branding. Public company disclosures and investor presentations also reference sustainability initiatives related to responsible fiber sourcing, energy efficiency, and environmental performance. Data regarding material investments outside the core tissue products business is inconclusive based on available public sources.

Geographic Footprint

KP Tissue is headquartered in Mississauga, Ontario, Canada, while its operating partnership maintains manufacturing and distribution operations across Canada and parts of the United States. The company’s strongest market presence is within the Canadian consumer tissue market, where several of its brands maintain leading or significant market positions. Operational assets include tissue mills and converting facilities located in Québec, Ontario, British Columbia, Tennessee, and other regional locations identified in company filings and investor disclosures.

The company’s international exposure is primarily connected to manufacturing operations and selective cross-border commercial activities in North America. While the business does not have the same global footprint as larger multinational tissue producers, it maintains regional influence through its scale in the Canadian market and integration with North American supply chains. Public filings do not indicate substantial direct operations outside North America.

Leadership & Governance

KP Tissue’s governance structure reflects its role as a publicly traded holding company with economic exposure to Kruger Products L.P.. The company was formed through the restructuring of the Kruger family’s tissue business interests, which remain influential through broader ownership and leadership involvement associated with the Kruger organization. Strategic direction has consistently emphasized brand leadership, disciplined capital investment, manufacturing modernization, and long-term shareholder returns supported by stable consumer demand for tissue products.

Key executives and directors identified in recent public filings include:

• Joseph Kruger II – Chairman and Chief Executive Officer
• Dino Bianco – Chief Executive Officer, Kruger Products Inc.
• Wayne Cheeseman – Chief Financial Officer
• René Charest – Chief Operating Officer, Canada
• David Lizzotte – Chief Operating Officer, U.S.

Leadership communications in public filings and investor materials consistently emphasize operational efficiency, consumer brand investment, supply chain resilience, and disciplined capital allocation as core strategic priorities. Executive roles and titles may evolve over time based on corporate filings and governance updates.